与使用阿达木单抗相关的发疹性脂溢性角化病。
Eruptive seborrheic keratoses associated with adalimumab use.
作者信息
Eastman Kristin L, Knezevich Stevan R, Raugi Gregory J
机构信息
University of Washington School of Medicine, Seattle, WA, USA;
出版信息
J Dermatol Case Rep. 2013 Jun 30;7(2):60-3. doi: 10.3315/jdcr.2013.1139.
BACKGROUND
Seborrheic keratoses are common, benign cutaneous growths, however in rare situations they can acutely erupt in large numbers. Eruptive seborrheic keratoses can be associated with internal malignancy (sign of Leser-Trelat), but may also appear in conjunction with inflammatory dermatoses and adverse drug reactions.
MAIN OBSERVATION
A 71-year-old Caucasian man presented with acute onset of a pruritic, burning papular erythematous rash on his chest, upper extremities and lower extremities after a routine adalimumab injection for rheumatoid arthritis. Two skin biopsies obtained showed findings diagnostic of seborrheic keratoses. Spontaneous resolution of the diffuse eruptive seborrheic keratoses was achieved within 3 months of discontinuing adalimumab therapy.
CONCLUSIONS
We believe the development of eruptive seborrheic keratoses due to adalimumab therapy is rare, and because our patient responded promptly to discontinuation of the drug we suggest this should be the preferred course of action in future cases.
背景
脂溢性角化病是常见的良性皮肤增生，但在极少数情况下它们会大量急性发作。爆发性脂溢性角化病可能与内部恶性肿瘤有关（Leser-Trelat征），但也可能与炎症性皮肤病和药物不良反应同时出现。
主要观察结果
一名71岁的白种男性在接受类风湿关节炎的常规阿达木单抗注射后，胸部、上肢和下肢出现急性发作的瘙痒性、灼痛性丘疹性红斑皮疹。两次皮肤活检结果诊断为脂溢性角化病。在停用阿达木单抗治疗后的3个月内，弥漫性爆发性脂溢性角化病自行消退。
结论
我们认为阿达木单抗治疗导致爆发性脂溢性角化病的情况很少见，并且由于我们的患者在停药后迅速有反应，我们建议在未来的病例中这应是首选的治疗方法。
Zotero 插件